Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Q4 FY2018 Earnings Presentation

15 slides from Alembic Pharmaceuticals's earnings presentation, May 2018

  1. Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation May-2018

    Alembic Pharmaceuticals Ltd Investor Presentation May-2018

  2. Slide 2: Contents

    Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7. Shareholding Pattern

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe

  4. Slide 4: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Rhizen JV for NCE research Launched first NDA wit

  5. Slide 5: Highlights – Q4FY18

    Highlights – Q4FY18 Financial Highlights India Formulations Gr% Rs 2.87bn Rs 3.04bn 6% Particular (Rs bn) Q4FY17 Q4FY18 Gr% 3.50 Net Sales 7.41 8.53 15% 3.00 10% EBITDA Pre R&D 2.42 2.81 16% 2.50 10% 8% 33% 37% Margin % 33% 33% 2.00 19% R&D 1.12 1.21 7% 1.50 1.00 R&D % 15% 14% 58% 53% -2% 0.50 EBITD

  6. Slide 6: Highlights – FY18

    Highlights –FY18 Financial Highlights India Formulations Gr% Rs 12.54bn Rs 12.74bn 2% Particular (Rs bn) FY17 FY18 Gr% 14.00 Net Sales 31.34 31.31 0% 12.00 10% 10% 6% EBITDA Pre R&D 10.36 10.27 -1% 10.00 33% 34% 8.00 5% Margin % 33% 33% 6.00 R&D 4.27 4.11 -4% 4.00 58% 56% 2.00 -1% R&D % 14% 13% ‐ EB

  7. Slide 7: Business

    Business 6.0 Key Numbers (Rs bn) Capex 4.8 3.2 31.6 31.3 31.3 10.1 6.2 6.4 3.2 4.3 4.1 FY16 FY17 FY18 Sales EBITDA R&D R&D: Manufacturing: Formulation: Vadodara , Hyderabad and USA Formulation: Oral Solids, Panelav (Mar18)* Sikkim, India market API: Vadodara and Hyderabad(Peptides) Oncology OSD (H1F

  8. Slide 8: International Formulations

    International Formulations Sales (Rs bn) ANDA Filed Filings: 132 Approval: 70* CAGR 21% * Incl 9 tentative 26 14.6 12.4 12.1 20 5.6 5.9 7 8 4 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 R&D Spend (Rs bn) Milestones and Update 13.6 13.1 10.0  Acquired US based Orit Laboratories LLC 6.6 6.3 4.3

  9. Slide 9: India Formulations

    India Formulations Sales (Rs bn) Marketing Organisation CAGR 7%  5000 + marketing team 12.5 12.7 11.8 11.0 9.7  17 marketing divisions Added new divisions in gynaecology, cardiology , GI, urology  170 products, 15% of products in NLEM Launch 20-25 products every year FY14 FY15 FY16 FY17 FY18 Key

  10. Slide 10: Therapy-wise Performance Q4FY18

    Therapy-wise Performance Q4FY18 QTR MAR 18 Therapy Market Alembic Alembic Therapy (%) Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) Cardiology 9 2.01 7 5 Anti Diabetic 10 1.56 0 -7 Gynaecology 9 2.75 2 -5 Gastrology 9 1.58 1 -1 Dermatological 12 0.42 3 15 Orthopaedic 6 0.84 -1 -5 Ophthalmology

  11. Slide 11: Therapy-wise Performance FY18

    Therapy-wise Performance FY18 YTD MAR 18 Therapy Market Alembic Alembic Therapy (%) Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) Cardiology 6 2.02 5 5 Anti Diabetic 11 1.64 4 1 Gynaecology 5 2.74 -1 -4 Gastrology 6 1.64 -3 -8 Dermatological 14 0.40 6 8 Orthopaedic 3 0.84 -6 -12 Ophthalmology

  12. Slide 12: Strategy

    Strategy R&D Pipeline Growth drivers Dosage Form FY14 FY18 R&D: Rapidly expand breadth and quality of pipeline Oral Solids   Doubled internal OSD grid. injectable, dermatology ophthalmology and oncology. Expanded grid 5 fold Injectables   Partnerships to gain time Oncology   Build manufacturin

  13. Slide 13: Financials – 5 years

    Financials – 5 years Sales CAGR% Sales (Rs bn) CAGR 14% Rs 18.7bn Rs 31.3bn 14% 18% API 18% 21% 31.6 31.3 31.3 52% 41% India 7% 20.7 18.7 39% International 22% 30% FY14 FY18 FY14 FY15 FY16 FY17 FY18 CAGR: 15% Net Profit (Rs bn) CAGR: 14% EBITDA (Rs bn) 32% 23% 19% 19% 20% 21% 13% 14% 13% 13% Margins

  14. Slide 14: Latest Shareholding Pattern

    Latest Shareholding Pattern % of Total Shareholding 13 Promoter & Promoter group 14 FI/FII/MF Public 73 Market capitalisation (Rs bn) CAGR 18% Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn 113 118 103 No. of shareholders >50 K 86 54 FY14 FY15 FY16 FY17 FY18

  15. Slide 15: Thank You

    THANK YOU

Alembic Pharmaceuticals — Q4 FY2018 Earnings Presentation on 6ix